Multiplex, real time PCR HemaVision kit for the screening and detection of 28 chromosomal translocations; RNA-test
Version date: 26/09/2017
Accredited:

Technology: HemaVision qPCR kit (DNA Diagnostic) for the screening and detection of 28 chromosome translocations with more than 145 clinically relevant chromosomal breakpoints
BELAC accreditation number 087-MED
Version date: 16/03/2021
Accredited:

Hemavision screenings panel for 28 different translocations: t(1;19):E2A/PBX1, t(3;5):NPM/MLF1, t(3;21):AML1/MDS1, t(5;12):TEL/PDGFRb, t(5;17):NPM/RARA, t(6;9):DEK/CAN, t(8;21):AML1/MGT8, t(9;9):SET/CAN, t(9;12):TEL/ABL, t(9;22):BCR/ABL, t(11;17)PLZF/RARA, t(12;21):TEL/AML1, t(12;22):TEL/MN1, t(15;17):PML/RARA, t(16;21):TLS/ERG, inv16:CBFb/MYH11, t(17;19):E2A/HLF, TAL1D:SIL1/TAL1 and the MLL1 with several fusion partners t(1;11):MLL1/AF1p, t(1;11):MLL1/AF1q, t(4;11): MLL1/AF4, t(6;11):MLL1/AF6, t(9;11):MLL1/AF9, t(10;11):MLL1/AF10, t(11;17):MLL1/AF17, t(11;19):MLL1/ELL, t(11;19):MLL1/ENL, and t(X;11):MLL1/AFX1.
BELAC accreditation number: 141-MED
Version date: 12/04/2023
Accredited:

DNA Diagnostic - HemaVision - 28Q -
Screening for BCR-ABL1 (p190, p210, p230) ; TEL-RUNX1 (AML1); E2A-PBX1; MLL(KMT2A)-AF4; SIL-TAL1; AML1-ETO; PML-RARA; MYH11-CBCB; MLL(KMT2A)-AF6; MLL-AF9(KMT2A); MLL(KMT2A)-AFX;
Full details: DNA Diagnostic; http://dna-diagnostic.com/products/hemavision/hemavision-28q/

BELAC accreditation number: 128-MED
Accredited:

SAMPLE TYPE:
Blood or bone marrow (1ml, EDTA)
TRANSPORT: room temperature, within 24h after sampling
FREQUENCY: 1x/week
TEST TYPE: RT-PCR with Hemavision-7 kit (detection of AML1-ETO, CBFb-MYH, PML-RARalfa, BCR-ABL1, E2A-PBX1, TEL-AML1, MLL-AF4)

Sample type: bone marrow or EDTA blood
Frequency: once a week
Test type: commercial kit (HemaVision Multiplex PCR kit)

Multiplex, real-time RT-PCR on RNA. Detection of 28 fusion genes. Kit Hemavision 28Q.
Detected fusion transcripts: BCR-ABL1, CBFB-MYH11/inv(16), DEK-NUP214, ETV6-RUNX1, KMT2A-AFF1, KMT2A-MLLT1, PML-RARA, RUNX1-RUNX1T1, STIL-TAL1, TCF3-PBX1, ETV6-ABL1, ETV6-MN1, ETV6-PDGFRB, FUS-ERG, KMT2A-ELL, KMT2A-EPS15, KMT2A-FOXO4, KMT2A-MLLT3, KMT2A-MLLT4, KMT2A-MLLT6, KMT2A-MLLT10, KMT2A-MLLT11, NPM1-MLF1, NPM1-RARA, RUNX1-MECOM, SET-NUP214, TCF3-HLF, ZBTB16-RARA.
Sample type: Blood and Bone marrow
BELAC accreditation number 204-MED
Version date: 06/09/2022
Accredited:

SAMPLE TYPE: blood or bone marrow (1ml)
FREQUENCY: upon request
ANALYSIS TYPE: RNA test, Hemavision 28Q real-time PCR on cDNA
Detected fusion transcripts: BCR-ABL1/t(9;22)(q34;q11); CBFB-MYH11/inv(16)(p13;q22); DEK-NUP214/t(6;9)(p23;q34); ETV6-RUNX1/t(12;21)(p13;q22); KMT2A-AFF1/t(4;11)(q21;q23); KMT2A-MLLT1/ t(11;19)(q23;p13.3); PML-RARA/t(15;17)(q24;q21); RUNX1-RUNX1T1/t(8;21)(q22;q22); STIL-TAL1/del(1)(p32) en TCF3-PBX1/ t(1;19)(q23;p13); ETV6-ABL1/ t(9;12)(q34;p13); ETV6-MN1/t(12;22)(p13;q11-12); ETV6-PDGFRB/ t(5;12)(q33;p13); FUS-ERG/t(16;21)(p11;q22); KMT2A-ELL/t(11;19)(q23;p13.1); KMT2A-EPS15/t(1;11)(p32;q23); KMT2A-FOXO4/t(X;11)(q13;q23); KMT2A-MLLT3/ t(9;11)(p22;q23); KMT2A-MLLT4/t(6;11)(q27;q23); KMT2A-MLLT6/t(11;17)(q23;q21); KMT2A-MLLT10/t(10;11)(p12;q23); KMT2A-MLLT11/t(1;11)(q21;q23); NPM1-MLF1/t(3;5)(q25.1;q35); NPM1-RARA/t(5;17)(q35;q12); RUNX1-MECOM/ t(3;21)(q26;q22); SET-NUP214/t(9;9)(q34;q34); TCF3-HLF/t(17;19)(q22;p13)en ZBTB16-RARA/t(11;17)(q23;q21).
Version date: 05/12/2017
Accredited:

Archer® FusionPlex ALL panel to screen for fusion transcripts involving ABL1, ABL2, BCL11B, BCL2, BCL6, BCR, CHD1, CREBBP, CRLF2, CSF1R, EBF1, EPOR, ETV6, FGFR1, IKZF1, IKZF2, IKZF3, JAK2, KLF2, KMT2A, MLLT4, MYC, NF1, NOTCH1, NTRK3, NUP214, NUP98, P2RY8, PAG1, PAX5, PBX1, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PTK2B, RUNX1, SEMA6A, SETD2, STIL, TAL1, TCF3, TYK2, ZCCHC7.
1x/week
BELAC accreditation number 087-MED
Version date: 31/05/2023
Accredited:

Multiplex, in-house developed, qPCR assay for the screening and detection of 4 chromosomal translocations in pediatric, adolescents and young adults (< 40 year old) with AML that do not have another translocation.

NUP98-NSD1 or t(5;11)(q35;p15.5)
NUP98-KDM5A or t(11;12)(p15;p13)
CBFA2T3-GLIS2 or inv(16)(p13q24)
OTT-MAL/RBM15-MKL1 or t(1;22)(p13;q13)

When a translocation has been identified, the singleplex qPCR reactions can be used to determine minimal/measurable detectable disease (see hematology - translocations for these tests)
Version date: 18/04/2019
Accredited:

Archer® FusionPlex Heme v2 NGS panel to screen for fusion transcripts involving 72 clinically relevant genes in hematological disorders: ABL1, ABL2, ALK, BCL11B, BCL2, BCL6, BCR, BIRC3, CBFB, CCND1, CCND3, CDK6, CHD1, CHIC2, CIITA, CREBBP, CRLF2, CSF1R, DEK, DUSP22, EBF1, EIF4A1, EPOR, ERG, ETV6, FGFR1, GLIS2, IKZF1, IKZF2, IKZF3, JAK2, KAT6A, KLF2, KMT2A, MALT1, MECOM, MKL1, MLF1, MLLT10, MLLT4, MYC, MYH11, NF1, NFKB2, NOTCH1, NTRK3, NUP214, NUP98, P2RY8, PAG1, PAX5, PDCD1LG2, PDGFRA, PDGFRB, PICALM, PML, PRDM16, PTK2B, RARA, RBM15, ROS1, RUNX1, RUNX1T1, SEMA6A, SETD2, STIL, TAL1, TCF3, TFG, TP63, TYK2, ZCCHC7.
Sample Type: Blood, Bone marrow.
BELAC accreditation number 204-MED
Version date: 09/09/2022
Accredited: